Trial Search Results

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Forest Laboratories

Collaborator: Merz Pharmaceuticals GmbH

Stanford Investigator(s):


  • Drug: Memantine - Extended Release (ER)
  • Drug: Placebo


Phase 2


Inclusion Criteria:

   - Males or females ages 6 to 12 years

   - Diagnosis of autistic disorder, according to DSM-IV-TR using Autism Diagnostic
   Interview-Revised and Autism Diagnostic Observation Schedule (modules 2 & 3).

   - A knowledgeable caregiver capable of providing reliable information about the
   patient's condition, able to attend all clinic visits with the patient

   - Patients over age 12, only if they completed Study MEM-PK-21

Exclusion Criteria:

   - Medical history of active epilepsy/seizure disorder except simple febrile seizures

   - Participation in any other clinical investigation using an experimental drug within 30
   days of the start of this study

Ages Eligible for Study

6 Years - 18 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Robin Libove
Not Recruiting